In regulated manufacturing industries, digital recordkeeping are no longer simple files used to store data. They have become traceable sources of evidence.
Pour pharmaceutique, nutraceutique, medical device, and contract manufacturing companies, electronic records and electronic signatures are essential for ensuring production safety, maintaining quality assurance, and preventing costly disruptions caused by formulation changes or process parameter adjustments. As U.S. regulations have evolved, 21 Partie CFR 11 compliance has gradually become a mandatory requirement rather than an optional investment.
For many manufacturers, especially small and medium-sized companies, implementing system validation and compliant data management solutions can seem expensive and complex. Par conséquent, two key questions are often raised first: when did 21 Partie CFR 11 go into effect, and what is 21 Partie CFR 11 conformité?
This comprehensive guide offers 21 Partie CFR 11 explained in detail. We will explore what is 21 Partie CFR 11, who needs to comply with it, its key requirements, and how to achieve 21 Partie CFR 11 compliance in a practical and cost-effective way.
Principaux enseignements
- When did 21 Partie CFR 11 go into effect and its historical context.
- Qu'est-ce que 21 Partie CFR 11 in pharmaceutical industry.
- Who needs 21 Partie CFR 11 compliance across various industries.
- Core 21 Partie CFR 11 requirements for records, signatures, access, and audit trails.
- How to comply with 21 Partie CFR 11 step by step.
- How Part 11 compliant equipment supports pharmaceutical and nutraceutical production.

1. Quand est-ce que 21 Partie CFR 11 Entrer en vigueur?
According to the FDA’s official website, 21 Partie CFR 11 went into effect on August 20, 1997.
What prompted the issuance of this regulation? Its origins lie in the major transition from paper-based records to computerized systems. Previously, pharmaceutical production records, laboratory reports, and quality documents were largely created, signed, and stored on paper. As production scales expanded, simple paper records could no longer meet the need for rapid documentation and immediate data retrieval, leading companies to adopt digital systems.
To ensure the reliability of these new systems, le 21 code of federal regulations part 11 links 21 CFR 11 electronic records electronic signatures to strict regulatory oversight. When companies use digital data to support decisions subject to FDA regulation, that data must be accurate and secure, as well as traceable and retrievable during FDA inspections.
2. Qu'est-ce que 21 Partie CFR 11?
Definition Of 21 Partie CFR 11
À la base, what is 21 Partie CFR 11? It is a regulation established by the U.S. FDA that dictates how to manage electronic records signatures.
To understand 21 Partie CFR 11 règlements, consider the FDA’s historical oversight of locked filing cabinets, monitoring who managed them and tracking who opened or modified their contents. As these filing cabinets have evolved into digital systems, the FDA has introduced these 21 Partie CFR 11 guidelines to ensure the systems are properly controlled and the data remains secure.
What Types Of Records Are Covered?
21 Partie CFR 11 electronic records may include:
- Electronic batch records
- Manufacturing records
- Quality control records
- Equipment operation logs
- Laboratory test results
- Cleaning and maintenance records
- Training records
- Change control and deviation records
It should be noted that this regulation does not apply to all digital files; it applies only when electronic records are used to meet FDA record-keeping requirements.
Which Industries Must Comply?
Compliance requirements under 21 Partie CFR 11 may apply to a wide range of entities, including pharmaceutical, dietary supplement, and medical device manufacturers, as well as contract manufacturing organizations, testing laboratories, and companies exporting FDA-regulated products to the United States.
Par conséquent, questions such as “Does 21 Partie CFR 11 apply to medical devices?” et “What does 21 Partie CFR 11 cover?” are critical; the core principle governing the rule’s applicability is that compliance requirements are triggered whenever electronic systems are used to support records or approvals subject to FDA data integrity requirements.

3. Why Was 21 Partie CFR 11 Introduced?
21 Partie CFR 11 was introduced because digital manufacturing created both new efficiency and new compliance risks.
21 Partie CFR 11 emerged in response to the efficiency gains and new compliance risks associated with digital manufacturing. As the industry transitioned from paper-based records to digital systems, the FDA needed to establish regulations ensuring the reliability of electronic records; this rule applies to FDA-regulated records that are created, modified, entretenu, archived, retrieved, or transmitted electronically.
The core objective of the rule is to safeguard 21 Partie CFR 11 data integrity and prevent tampering or falsification by requiring systems to feature audit trails, acting much like a “black box” that records the true sequence of events. During FDA inspections, regulators examine electronic batch records, part 11 audit trail requirements, user access controls, et 21 Partie CFR 11 compliant electronic signatures; these comprehensive historical records serve as the cornerstone for regulatory compliance, qualité du produit, and customer trust.
4. Who Needs 21 Partie CFR 11 Conformité?
Not every company needs the same level of control, but many FDA regulated manufacturers should evaluate who needs 21 Partie CFR 11 compliance based on their systems and market.
Drug Manufacturers
Pour 21 Partie CFR 11 industrie pharmaceutique, electronic record systems involving batch information, Contrôle de qualité, equipment logs, or release approvals are generally required to comply with 21 Partie CFR 11. Cependant, once electronic records formally replace paper records, this compliance obligation becomes mandatory rather than optional.
Dietary Supplement Manufacturers
If a dietary supplement manufacturer processes production, qualité, or batch records electronically and the product is intended for sale in the United States, the CFR Part 11 compliance are likely to apply.
Medical Device Manufacturers
For those asking does 21 Partie CFR 11 apply to medical devices, the answer is yes when electronic records support FDA quality system requirements.
Contract Manufacturing Organizations
CMOs often need strong FDA CFR Part 11 compliance because they serve multiple clients and face frequent customer audits.
Companies Exporting To The United States
Even if the manufacturer is located outside the United States, compliance with Part 11 requirements is generally still required provided the products are sold in the U.S. and the electronic records pertain to FDA-regulated activities.
5. Que sont 21 Partie CFR 11 Requirements?
Bien, according to the document, what exactly are the 21 Partie CFR 11 exigences? The answer can be grouped into several practical controls. Compliance requirements under 21 Partie CFR 11 center on five key areas: electronic records, electronic signatures, pistes d'audit, user access controls, and record retention and retrieval.
Dossiers électroniques
21 Partie CFR 11 requirements for electronic records state that electronic records must be accurate, complete, sécurisé, readable, and retrievable. Companies should maintain proper record retention and secure data storage.
Signatures électroniques
FDA part 11 electronic signatures must clearly establish identity and accountability, displaying the signer’s name, the timestamp, and the meaning of the action (par ex., “approval for release”) to ensure they hold the same legal validity as handwritten signatures.
Audit Trails
How audit trail works in pharmaceutical equipment is a common question. Audit trails automatically record all critical actions, including creation, modification, deletion, approval, and system changes, to ensure traceability. If a batch’s weight data is changed from 500 kg to 510 kg, the audit log records the modifier, the time of the change, and the values before and after the edit, facilitating root cause analysis.

User Access Controls
Access controls ensure that only authorized personnel can perform specific actions through password protection and permission management, utilizing multi-factor authentication and the principle of least privilege.
Record Retention And Retrieval
Records must remain readily accessible throughout the FDA-mandated retention period; failure to retrieve data promptly during an audit is considered a serious compliance violation.
6. How To Comply With 21 Partie CFR 11
Achieving compliance is a primary concern for most pharmaceutical and health product companies. In this section, we will explore the subject in depth, covering specific implementation steps, potential issues, and corresponding solutions.
Étape 1 – Conduct A 21 Partie CFR 11 Compliance Assessment
You should start by comparing all systems that create, modify, store, retrieve, or transmit FDA-regulated electronic records against 21 Partie CFR 11 guidelines for pharmaceuticals. The assessment should include validation, audit trail, contrôle d'accès des utilisateurs, electronic signatures, record retention, and security.
Follow the 21 CFR 11 compliance checklist can speed up your process.
Étape 2 – Validate Computerized Systems
UN 21 Partie CFR 11 compliant system should go through validation to prove they perform as intended. En pratique, validation should be carried out as a structured sequence of actions:
1. Define and Assess System Scope and Risk
Start by clearly documenting what the system is supposed to do and identify where the risk is. Par exemple, un machine de remplissage de capsules must record fill weight, vitesse, and batch number.
2. Test and Verify System Performance
Suivant, perform structured testing using IQ, QO, and PQ. This assesment is to check if the system is working as expected.
3. Document, Approve, and Maintain Control
Enfin, all validation activities must be documented, reviewed, and approved before system release.
Étape 3 – Implement Audit Trail Functionality
You need to ensure the integrity of the audit trail function, confirming that the system securely stores and records data, such as timestamps and changes, and allows for accurate retrieval. Take the adjustment of capsule filling machine parameters as an example: once an operator modifies the filling parameters, the system automatically captures the old and new values, the operator ID, and the timestamp.
Étape 4 – Establish Electronic Signature Controls
To meet electronic signatures FDA expectations, each user should have a unique identity. Electronic signatures should be linked to specific records and should not be copied or reassigned.

Étape 5 – Control User Access
Use role-based access. Different roles should have different permisssions. For adminisstrators, they always have the superior permissions, while operators only have partial permissions.
7. Ruida Packing Machinery: Providing FDA And GMP Compliant Machines
Somtimes even if manufactrers are willing to equip their machines with audit trail system, not all machines support it. Emballage Ruida, collaborating with well-known pharmaceutical companies, including UCB and US Pharma, undoubtedly is commited to develop part 11 compliant equipment. Our machines are supported by CE, GMPc, OIN, and related certificates. According to clients needs, Ruida can also provide 21 Partie CFR 11 monitoring solution for production and packaging equipment.
Ruida also supports pharmaceutical manufacturing with practical service details:
- Certified materials: 304 stainless steel for non-contact parts and 316L stainless steel for contact parts.
- Remote and on-site commissioning services, with after-sales centers in North America and Hong Kong.
- Complet machine guidance: Manuals, operation guidance, maintenance documents, and after-sales videos.
- QI, QO, PQ Documentation: Optional support for validation documents, IQ OQ PQ, and compliance documentation.

For manufacturers planning 21 Partie CFR 11 conformité, choosing equipment with compliance-ready options can reduce future modification costs and make audits easier to prepare for.
8. Conclusion
Looking back at when did 21 Partie CFR 11 go into effect, we can see how profoundly it has shaped the industry since 1997. Sicne August 20 in the year, this regulation has been a standard how FDA regulated companies should manage electronic data. Aujourd'hui, 21 Partie CFR 11 compliance has been a focus and concern for many pharma and nutra manufacturers, and you’d better off preparing for it. Not just the validation, but also the machines.
9. FAQ

T1: Is 21 Partie CFR 11 Mandatory?
Oui, of course. But it not suits for all electronic recording systems. It is mandatory when electronic records or electronic signatures are used to meet FDA requirements.
Q2: Where the GMP And 21 CFR Part 11’s Difference Lies in?
Bien, they have different focus. GMP focuses on product quality, alors que 21 Partie CFR 11 focuses on electronic records and electronic signatures.
Q3: Does Every Pharmaceutical Machine Need Part 11 Conformité?
Non. A machine needs Part 11 consideration when it creates, stores, modifies, or transmits regulated electronic records. Purely mechanical equipment may not need the same level of control.
Q4: What Is An Audit Trail?
An audit trail is to record any actions done on the system, showing the exact action, temps, and any changes.
Q5: How Do I Know If Equipment Supports Part 11 Requirements?
You can check whether it supports audit trails, contrôle d'accès des utilisateurs, electronic signatures, secure data storage, record export, and validation documents. But put it simlpe, just go ask the machine suppliers before purchase.
References
[1] NOUS. Administration des aliments et des médicaments: Partie 11, Dossiers électroniques; Electronic Signatures — Scope and Application
[2] Code électronique des réglementations fédérales: 21 Partie CFR 11 — Electronic Records; Signatures électroniques[3] Federal Register: Dossiers électroniques; Electronic Signatures Final Rule, Published March 20, 1997
[3] Federal Register: Dossiers électroniques; Electronic Signatures Final Rule, Published March 20, 1997


